Pertussis booster vaccination in HIV-infected children receiving highly active antiretroviral therapy

Pediatrics

Volumn 120, Issue 5, 2007, Pages

  Abzug, Mark J ^a,h   Song, Lin Ye ^b   Fenton, Terence ^b   Nachman, Sharon A ^c   Levin, Myron J ^a   Rosenblatt, Howard M ^d   Pelton, Stephen I ^e   Borkowsky, William ^f   Edwards, Kathryn M ^g   Peters, Jody ^g  

^a UNIVERSITY OF COLORADO   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e BOSTON MEDICAL CENTER   (United States)

^f BELLEVUE HOSPITAL CENTER   (United States)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CHILDREN S HOSPITAL COLORADO   (United States)

Author keywords

Bordetella pertussis; Highly active antiretroviral therapy; HIV; Pertussis; Pertussis vaccine

Indexed keywords

ANTIRETROVIRUS AGENT; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEMAGGLUTININ; VIRUS RNA;

ARTICLE; CHILD; DEATH; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; SKIN INDURATION; VACCINATION;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; IMMUNIZATION, SECONDARY; MALE; PERTUSSIS VACCINE; VACCINATION;

EID: 36049016035     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2007-0729     Document Type: Article

References (52)

1. Colebunders R, Vael C, Blot K, Van Meerbeeck J, Van den Ende J, Ieven M. Bordetella pertussis as a cause of chronic respiratory infection in an AIDS patient. Eur J Clin Microbiol Infect Dis. 1994;13:313-315
2. Nordmann P, Francois B, Menozzi FD, Commare MC, Barois A. Whooping cough associated with Bordetella parapertussis in a human immunodeficiency virus-infected child. Pediatr Infect Dis J. 1992;11:248
3. Doebbeling BN, Feilmeier ML, Herwaldt LA. Pertussis in an adult man infected with the human immunodeficiency virus. J Infect Dis. 1990;161:1296-1298
4. Adamson PC, Wu TC, Meade BD, Rubin M, Manclark CR, Pizzo PA. Pertussis in a previously immunized child with human immunodeficiency virus infection. J Pediatr. 1989;115:589-592
5. Vielemeyer O, Crouch JY, Edberg SC, Howe JG. Identification of Bordetella pertussis in a critically ill human immunodeficiency virus-infected patient by direct genotypical analysis of gramstained material and discrimination from B. holmesii by using a unique recA gene restriction enzyme site. J Clin Microbiol. 2004;42:847-849
6. De Martino M, Podda A, Galli L, et al. Acellular pertussis vaccine in children with perinatal human immunodeficiency virus-type 1 infection. Vaccine. 1997;15:1235-1238
7. Melvin AJ, Mohan KM. Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. Pediatrics. 2003;111(6). Available at: www.pediatrics.org/cgi/content/full/111/6/e641
8. Tovo PA, de Martino M, Gabiano C, Galli L. Pertussis immunization in HIV-1-infected infants: a model to assess the effects of repeated T cell-dependent antigen administrations on HIV-1 progression. Italian Register for HIV infection in children. Vaccine. 2000;18:1203-1209
9. Donovan RM, Bush CE, Moore E, Markowitz NP. Changes in plasma HIV RNA levels after vaccination of pediatric patients [abstract]. Presented at: Conference on Retroviruses and Opportunistic Infection; January 22-26, 1997; Washington, DC. Abstract 758
10. Begue P, Grimpel E, Giovannengeli M, Abitbol VI. Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus- acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus- inactivated poliovirus vaccine in preadolescents. Pediatr Infect Dis J. 1998;17:804-809
11. Rosenblatt HM, Song LY, Nachman SA, et al. Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. J Allergy Clin Immunol. 2005;116:698-703
12. Baughman AL, Bisgard KM, Edwards KM, et al. Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin Diagn Lab Immunol. 2004;11:1045-1053
13. Taranger J, Trollfors B, Lagergard T, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis. 2000;181:1010-1013
14. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 1998;16:1901-1906
15. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 1998;16:1907-1916
16. Mallet E, Matisse N, Mathieu N, et al. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Vaccine. 2004;22:1415-1422
17. Pichichero ME, Anderson EL, Rennels MB, Edwards KM, Englund JA. Fifth vaccination with diphtheria, tetanus and acellular pertussis is beneficial in four- to six-year-olds. Pediatr Infect Dis J. 2001;20:427-433
18. Pichichero ME, Deloria MA, Rennels MB, et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics. 1997;100:772-788
19. Edelman KJ, He Q, Makinen JP, et al. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis. 2004;39:179-185
20. Pichichero ME, Blattner MM, Kennedy WA, Hedrick J, Descamps D, Friedland LR. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics. 2006;117:1084-1093
21. Le T, Cherry JD, Chang S, et al. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT study. J Infect Dis. 2004;190:535-544
22. Edwards KM, Meade BD, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics. 1995;96:548-557
23. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med. 1996;334:341-348
24. Blatter M, Reisinger K, Pichichero M, Pickering L, Delbuono F, Howe B. Immunogenicity of diphtheria-tetanus-acellular pertussis, concomitantly at separate sites along with oral poliovirus vaccine in infants. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; September 15-18, 1996; New Orleans, LA. Abstract G102
25. Schmitt H, Beutel K, Schuind A, et al. Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age. J Pediatr. 1997;130:616-623
26. Keitel WA, Muenz LR, Decker MD, et al. A randomized clinical trial of acellular pertussis vaccines in healthy adults: doseresponse comparisons of 5 vaccines and implications for booster immunization. J Infect Dis. 1999;180:397-403
27. Van der Wielen M, Van Damme P, Joossens E, Fancois G, Meurice F, Ramalho A. A randomized controlled trial with diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine. 2000;18:2075-2082
28. Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics. 1995;96:557-566
29. Pichichero ME, Edwards KM, Anderson EL, et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics. 2000;105(1). Available at: www.pediatrics.org/cgi/content/full/105/1/e11
30. Heininger U, Cherry JD, Stehr K. Serologic response and antibody-titer decay in adults with pertussis. Clin Infect Dis. 2004;38:591-594
31. Abzug MJ, Pelton SI, Song LY, et al. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J. 2006;25:920-929
32. Weinberg A, Wohl DA, Barrett RJ, van der Horst C. Inconsistent reconstitution of cytomegalovirus-specific cell-mediated immunity in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. J Infect Dis. 2001;184:707-712
33. Weinberg A, Wiznia AA, LaFleur BJ, et al. Varicella-Zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis. 2004;190:267-270
34. Weinberg A, Pahwa S, Oyomopito R, et al. Antimicrobialspecific cell-mediated immune reconstitution in children with advanced human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2004;39:107-114
35. Crothers K, Huang L. Recurrence of Pneumocystis carinii pneumonia in an HIV-infected patient: apparent selective immune reconstitution after initiation of antiretroviral therapy. HIV Med. 2003;4:346-349
36. Weinberg A, Gona P, Nachman SA, et al. Antibody responses to hepatitis A virus vaccine in HIV-infected children with evidence of immunologic reconstitution while receiving highly active antiretroviral therapy. J Infect Dis. 2006;193:302-311
37. + cell depletion. J Infect Dis. 2003;188:1794-1803
38. Berkelhamer S, Borock E, Elsen C, Englund J, Johnson D. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccination in human immunodeficiency virus-infected children. Clin Infect Dis. 2001;32:1090-1094
39. Bekker V, Scherpbier H, Pajkrt D, Jurriaans S, Zaaijer H, Kuijpers TW. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatrics. 2006;118(2). Available at: www.pediatrics.org/cgi/content/full/118/2/e315
40. McCool TL, Schreiber FR, Greenspan NS. Genetic variation influences the B-cell response to immunization with a pneumococcal polysaccharide conjugate vaccine. Infect Immun. 2003;71:5402-5406
41. Musher DM, Groover JE, Watson DA, et al. Genetic regulation of the capacity to make immunoglobulin G to pneumococcal capsular polysaccharides. J Investig Med. 1997;45:57-68
42. Newport MJ, Goetghebuer T, Weiss HA, et al. Genetic regulation of immune responses to vaccines in early life. Genes Immun. 2004;5:122-129
43. Hohler T, Meyer CU, Notgi A, et al. The influence of major histocompatibility complex class II genes and T-cell Vbeta repertoire on response to immunization with HBsAg. Hum Immunol. 1998;59:212-218
44. Kroon FP, Rimmelzwaan GF, Roos MTL, et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS. 1998;12:F217-F223
45. Lange CG, Lederman MM, Medvik K, et al. Nadir CD4- T-cell count and numbers of CD28+- CD4- T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS. 2003;17:2015-2023
46. Tangsinmankong N, Kamchaisatian W, Day NK, Sleasman JW, Emmanuel PJ. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy. Ann Allergy Asthma Immunol. 2004;92:558-564
47. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine. 1999;18:524-530
48. Rodriguez-Barrada MC, Alexandraki I, Nazir T, et al. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis. 2003;37:438-447
49. Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Adult and adolescent spectrum of HIV disease project. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis. 2001;32:794-800
50. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine. 2000;19:886-894
51. Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr. 2001;139:305-310
52. Malaspina A, Moir S, Kottilil S, et al. Deleterious effect of HIV-1 plasma viremia on B cell costimulatory function. J Immunol. 2003;170:5965-5972